Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DocCheck AGXTER:AJ91 -0.84%71 ROE % is 14.32% as of Dec. 2025, which is 5% above its 10-year median of 13.60. GuruFocus rates XTER:AJ91 with a GF Score™ of 71/100 and a GF Value™ of €9.52 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 622 Healthcare Providers & Services companies, DocCheck AG ranks better than 71.7% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. DocCheck AG's annualized net income for the quarter that ended in Dec. 2025 was €5.75 Mil. DocCheck AG's average Total Stockholders Equity over the quarter that ended in Dec. 2025 was €40.17 Mil. Therefore, DocCheck AG's annualized ROE % for the quarter that ended in Dec. 2025 was 14.32%.
The historical rank and industry rank for DocCheck AG's ROE % or its related term are showing as below:
XTER:AJ91'
s ROE % Range Over the Past 10 Years
Min: 5.98 Med: 13.6 Max: 34.77
Current: 13.29
During the past 13 years, DocCheck AG's highest ROE % was 34.77%. The lowest was 5.98%. And the median was 13.60%.
XTER:AJ91's ROE % is ranked better than 71.7% of 622
companies
in the Healthcare Providers & Services industry
Industry Median: 5.895
vs XTER:AJ91: 13.29
DocCheck AG (XTER:AJ91) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
DocCheck AG ROE % Related Terms
DocCheck AG ROE % Historical Data
* Premium members only.
The historical data trend for DocCheck AG's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, DocCheck AG's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DocCheck AG ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DocCheck AG's ROE % distribution charts can be found below:
* The bar in red indicates where DocCheck AG's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
DocCheck AG (XTER:AJ91) has a ROE % of 14.32% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on DocCheck AG and its competitors. This is near median its historical median of 13.60. Over the past decade, DocCheck AG's ROE % has ranged from 5.98 to 34.77. According to the industry distribution chart, DocCheck AG ranks #176 out of 622 companies in the Healthcare Providers & Services industry, placing it in the top 28.3%.
Is DocCheck AG's ROE % too high?
DocCheck AG's current ROE % of 14.32% is near median its 10-year median of 13.60. Over the past 10 years, this metric has ranged from a low of 5.98 to a high of 34.77. The Healthcare Providers & Services industry median ROE % is 5.90. DocCheck AG's value of 14.32% is 142.9% above this industry median. Based on the distribution chart, DocCheck AG ranks #176 out of 622 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, DocCheck AG has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DocCheck AG's ROE % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, DocCheck AG ranks #176 out of 622 companies for ROE %. This puts DocCheck AG in the upper half of its industry. The industry median ROE % is 5.90. DocCheck AG's value of 14.32% is 142.9% above this benchmark. Historically, DocCheck AG's own ROE % has ranged from 5.98 to 34.77 over the past decade. While the company's 10-year median is 13.60 vs. the industry median of 5.90, DocCheck AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.90, based on 622 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DocCheck AG's current ROE % of 14.32% is 142.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on DocCheck AG and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DocCheck AG's current ROE % is 14.32%, which is near median its own 10-year median of 13.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DocCheck AG stock overvalued right now?
Based on GuruFocus' analysis, DocCheck AG (XTER:AJ91) is currently considered Modestly Overvalued. The stock's GF Value™ is €9.52, compared to a current price of €11.80 — trading 23.9% above its estimated fair value. The current ROE % is 14.32%, which is near median its 10-year median of 13.60 and 142.9% above the Healthcare Providers & Services industry median of 5.90. DocCheck AG's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For DocCheck AG (XTER:AJ91), the current ROE % is 14.32% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DocCheck AG (XTER:AJ91) Overvalued in 2026?
Based on GuruFocus' analysis, DocCheck AG stock appears to be overvalued.
The current stock price of €11.80 is trading 23.9% above its estimated GF Value™ of €9.52.
GuruFocus considers DocCheck AG to be Modestly Overvalued.
Key valuation signals for XTER:AJ91:
ROE %: 14.32% (near median its 10-year median of 13.60)
GF Value™: €9.52 vs. price of €11.80 (23.9% above fair value)
Industry Position: 142.9% above the Healthcare Providers & Services median (#176 of 622)
No single metric tells the full story. See the XTER:AJ91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DocCheck AG is a Germany-based company engaged in the healthcare sector. It operates through subsidiaries: antwerpes AG develops integrated communication concepts for the healthcare sector, including social media and digital communication with focus on e-marketing concepts, search engine optimization (SEO), search engine advertising (SEA) and search engine marketing (SEM); DocCheck Medical Services GmbH operates an online platform for healthcare professionals, such as physicians and pharmacists; DocCheck Medizinbedarf und Logistik GmbH wholesales medical products from third parties and also produces own medical products, and DocCheck Guano AG is a venture capital company with focus on e-health companies and promotes healthcare startups.
71GF Score
Get the complete analysis for XTER:AJ91
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:AJ91 has been successfully added to your 
